Free the Data!
Please consider submitting BRCA1/2 testing results from your patients to www.sharingclinicalreports.org.
See: http://nyti.ms/14hUJsu for an explanation of the issue.
Thank you, Your GeneDx Team
RET Remaining Exons Sequencing (MEN2A & MEN2B)
FORMS AND DOCUMENTS
TEST DETAILS
- Genes:
- RET
- Disorders:
- Clinical Utility:
-
- Confirmation of a clinical diagnosis
- Determination of appropriate screening and surgical management
- Identification of at-risk family members
- Prenatal diagnosis
- Lab Method:
- Capillary Sequencing
ORDERING
- Test Code:
- 1793
- Turnaround Time:
- 5-6 weeks
- Preferred Specimen:
- 2-5 mL Blood - Lavender Top Tube
BILLING
- CPT Codes:
- 81479x1
- Billing Information:
- View Billing Policy
- ICD Codes:
-
- 227: Adrenal gland, Suprarenal gland
- 193: Malignant neoplasm of thyroid gland, Thyroglossal duct
REFERENCES
- Yip, L. et al., Multiple Endocrine Neoplasia Type 2: Evaluation of the Genotype-Phenotype Relationship. Arch Surg. 138: 409-16, 2003
- Shirahama S et al. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma. J Hum Genet 43:101-106, 1998
- Wiench M et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 19(5):1374-1380, 2001
- Elisei, R et al., RET genetic screening in patients with medullary thyroid cancer and their relatives: Experience with 807 individuals at one center. J Clin Endocrinol Metab 92(12)4725-4729, 2007
- Mulligan, L.M. et al., Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med. 238: 343-6, 1995
- Mulligan, L.M. et al., Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 6: 70-4, 1994
- Heshmati HM, et al. Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. Mayo Clin Proc 72(5):430-436, 1997
